AGENDA

3D Cell Culture Summit and Workshop Hilton Torrey Pines, San DiegoJune 4-5, 2019

SPECIAL OFFER:

Free Access to New 3D Research ArticlesCorning is pleased to offer exclusive access to six new 3D cell culture research articles from

SLAS Technology: Translating Life Sciences Innovation 2019 Journal.

Visit www.corning.com/slas-offer to download your copy.

(over)

A G E N D A

3D Cell Culture Summit and Workshop

June 4: 3D Cell Culture Summit

Time Event Speaker Room

8:30 a.m. Registration Opens Continental Breakfast and Networking

Salon A

9:00 Welcome and Housekeeping Lynsey Willetts, Ph.D.Business Director, Cell CultureCorning Life Sciences

9:05 Corning Introduction and 3D Cell Culture Overview

Keith Olson, Ph.D.Director, Business OperationsCorning Life Sciences

9:20 3D Cultures Reveal YAP-independent Mechanotransduction Drives Breast Cancer Progression

Joanna Lee, Ph.D.ScientistGenentech

10:00 3-Dimensional Physiologically Relevant Human iPSC-based Screening Platforms Elevating Drug Discovery

Fabian Zanella, Ph.D. Director, Research and Development StemoniX

10:40 Break

10:55 New Product Highlight: Corning® Elplasia™ Microplates

Lynsey Willetts, Ph.D. Business Director, Cell Culture Corning Life Sciences

11:05 3D Tumor Cell Line Profiling in Oncology Research

Gonzalo Castillo, Ph.D. VP R&D and Business Development BIOENSIS

11:45 Bioprinted Three-Dimensional Human Tissues for Disease Modeling

Kelsey Retting, Ph.D. Associate Director of R&D Organovo, Inc.

12:25 p.m. Lunch and Networking Torreyana Terrace

1:15 Laser Printing for R&D Ready 3D Tissue Scaffolds

Melanie P. Matheu, Ph.D.Founder, CEO Prellis Biologics, Inc.

Salon A

1:40 Predicting Drug Safety and Efficacy with Human Kidney Organoids

Benjamin Freedman, Ph.D. Assistant ProfessorUniversity of Washington School of Medicine

2:20 3D Enteroid-derived “Gut-in-a-dish” Model for Developing Personalized Therapies for Chronic Inflammatory Diseases

Soumita Das, Ph.D.Assistant Professor, Dept. of Pathology, Chief Scientific Director, HUMANOID University of California San Diego

3:00 Break

3:15 New Product Highlight: 3D-qualified Hepatocytes

David Randle, Ph.D.Business Manager, ADME and Genomics Corning Life Sciences

Salon A

3:30 Profiling Anti-tumor Immune Function Using Ultra-HTS 3D Spheroid Models

Shane Horman, Ph.D. Research Investigator III, Head of Advanced Assays Group, Functional Genomics Dept.GNF-Novartis

4:10 Using Patient-derived Pancreatic Cancer Organoids Towards Discovering Individually Tailored Clinical Treatments

Ralph J. Garippa, Ph.D. Head of the Gene Editing & Screening (GES) Core Facility Memorial Sloan Kettering Cancer Center

4:50 Closing Remarks Lynsey Willetts, Ph.D. Business Director, Cell Culture Corning Life Sciences

5:00 - 7:00 Cocktails, Dinner, and Networking Torreyana Terrace

June 5: Bringing your Cells to the Third Dimension Workshop

Time Event Speaker Room

8:30 a.m. Continental Breakfast and Networking Salon A

9:00 Welcome Lynsey Willetts, Ph.D. Business Director, Cell CultureCorning Life Sciences

9:05 From Promise to Reality in your Lab: Practical 3D Tools and Applications

Chris Suarez, Ph.D. Field Application Scientist Corning Life Sciences

9:50 Cell Health Determinations in 3D Cultures: Challenges and Opportunities

Andrew L. NilesSenior Research Scientist, Assay Designs Group Promega Corporation

10:20 Break/3D Cell Culture Solutions Expo

10:40 3D Assay Optimization Chris Suarez, Ph.D. Field Application Scientist Corning Life Sciences

11:25 Challenges of High Throughput 3D Acquisition and Analysis Using High-content Imaging

Jayne HesleySenior Applications Scientist, Cellular Imaging Molecular Devices, LLC

11:55 Closing Remarks Lynsey Willetts, Ph.D. Business Director, Cell Culture Corning Life Sciences

12:00 p.m. Boxed Lunches and Networking

Time Event Speaker Room

Presentation AbstractsThe Emergence of 3D Cell Culture and Corning's Pioneering InnovationsKeith Olson, Ph.D.Director, Business Operations Corning Life Sciences

Cellular research is optimal when using physiologically relevant cell phenotypes and genotypes of human origin. This asser tion has accelerated the adoption of primary cells, stem cells, and increasingly, patient-specific cells in drug discovery. Over the last five years, technological improvements in 3D cell culture technology, to better mimic in vivo physiology, have also accelerated. Furthermore, 3D cell culture is facilitating novel approaches to both the scale-up and manufacture of biologics, including those used in immuno- and stem cell-based therapies.

This presentation will cover Corning’s role in 3D cell culture technology innovation, and how the company’s scientists and subject matter experts view current developments in the field.

3D Cultures Reveal YAP-independent Mechanotransduction Drives Breast Cancer ProgressionJoanna Lee, Ph.D. Scientist Genentech

The transcriptional regulator YAP is considered a universal mechanotransducer, based largely on 2D culture studies. We show a lack of YAP activity in cells in 3D culture and in vivo, which is associated with drastic changes in nuclear morphology relative to cells in 2D culture. This work highlights the context-dependent role of YAP in mechanotransduction and establishes that YAP does not mediate mechanotransduction in breast cancer.

3-Dimensional Physiologically Relevant Human iPSC-based Screening Platforms Elevating Drug DiscoveryFabian Zanelli, Ph.D. Director, Research and Development StemoniX

Structurally engineered human induced pluripotent stem cells (hiPSCs) enable greater physiological relevance, elevating performance in toxicity and discovery studies. Here we will discuss case studies employing StemoniX’s hiPSC-derived neural (microBrain) and cardiac (microHeart) cells constructed with appropriate tissue composi tion, as well as correct inter- and intracellular organization, promoting robust physiological activity and expected responses to known cellular modulators.

New Product Highlight: Corning® Elplasia™ MicroplatesLynsey Willetts, Ph.D. Business Director, Cell Culture Corning Life Sciences

With the growing adoption of 3D cell culture in areas like cancer research, drug screening and precision medicine, the need for uniform size spheroids in mass quantities has arisen. Corning Life Sciences will soon offer 3D spheroid cell culture plates that allow for large-scale, one-step spheroid formation and analysis of spheroid pharmacology to address this need. This high volume method to produce replicate spheroids of uniform size and mass quantities will benefit researchers, as well as the development and clinical community.

3D Tumor Cell Line Profiling in Oncology ResearchGonzalo Castillo, Ph.D. VP R&D and Business Development BIOENSIS

The use of 3D cell culture models is steadily increasing due to their close resemblance to the natural cellular environment supported by the introduction of new technologies. Accurately determining the pharmacologic profile of small molecules and biologics early on, alone or in combination with other drugs, is essential for the time- and cost-effective development of novel therapies. Pharmacology utilizing 3D cultures allow for more accurate in vitro to in vivo predictions, thereby preventing costly expenditures in downstream development.

Bioprinted Three-Dimensional Human Tissues for Disease ModelingKelsey Retting, Ph.D. Associate Director of R&D Organovo, Inc.

Successful prediction of candidate drugs can be hampered by the limitations of in vitro tools to model complexities of human tissue biology. This translational challenge can result in low safety and efficacy predictability and contribute to attrition in drug development. To bridge this gap, the Organovo NovoGen® Bioprinting Platform has been utilized to develop ExVive™ 3D Bioprinted Tissues, fully cellular 3D tissue models fabricated by automated spatially controlled cellular deposition. The multicellular architecture of the 3D model can better recapitulate native tissue structure and function compared to standard in vitro models, allowing for complex, tissue-level phenotypes associated with chronic injury and disease.

Laser Printing for R&D Ready 3D Tissue Scaffolds

Melanie P. Matheu, Ph.D.Founder, CEO Prellis Biologics, Inc.

Prellis Biologics developed a revolutionary technology that allows for creation of high resolution tissue structures that match that of human physiology. Using biocompatible, transplantable materials Prellis Biologics’ Vascular Tissue Blanks work as large format 3D tissue culture scaffolds that can be seeded with cells in a matter of minutes. Scaffold construction is highly flexible allowing printing from any CAD file.

Predicting Drug Safety and Efficacy with Human Kidney Organoids

Benjamin Freedman, Ph.D.Assistant Professor University of Washington School of Medicine

Accurately predicting the safety and efficacy of therapeutic compounds remains a major challenge, which is limited by a lack of human species specificity and the low throughput of existing methods. We have recently invented kidney organoids, derived from human pluripotent stem cells, which contain patterned segments that resemble primitive kidney tissue. These organoids can furthermore be manufactured in an automated fashion for high throughput screening, to assess phenotypic readouts of nephrotoxicity and genetic kidney disease, as an early step in the drug development pipeline.

3D Enteroid-derived “Gut-in-a-dish” Model for Developing Personalized Therapies for Chronic Inflammatory Diseases

Soumita Das, Ph.D.Assistant Professor, Dept. of Pathology, Chief Scientific Director, HUMANOID University of California San Diego

We have developed Gut-in-a-dish model from 3D organoids isolated from the intestinal specimens of healthy and diseased patients. This model consisting of epithelial cells, immune cells and microbes could be utilized to investigate mechanisms for gastro-intestinal inflammatory diseases, both oncogeneic and non-oncogeneic. A semi-HTP format of the model can be useful for the identification of new diagnostic and therapeutic targets, personalization of therapies through Phase “0” human trials, determination of the effect of beneficial vs. harmful microbes, prebiotics, probiotics, and nutritional components and to screen efficacy of novel barrier-protective drugs to combat inflammation-linked diseases.

New Product Highlight: 3D-qualified Hepatocytes

David Randle, Ph.D.Business Manager, ADME & Genomics Corning Life Sciences

3D liver spheroids made from primary human hepatocytes (PHHs) are being adapted to in vitro assays for drug discovery and development activities such as liver safety assessment and disease modeling. Because of large lot-to-lot variations among PHH lots, qualifying hepatocytes for liver spheroid culture will facilitate efforts to standardize the use of this novel 3D liver spheroid model. This presentation will give an overview of qualification studies for multiple lots of PHHs for liver spheroid culture using a standard protocol in Corning® spheroid microplates. Characterization of liver function such as albumin secretion, drug metabolizing enzyme activities, and cytotoxicity responses demonstrate the possible utilization of liver spheroids made from these spheroid-qualified PHHs for different endpoint assays.

Profiling Anti-Tumor Immune Function Using Ultra-HTS 3D Spheroid Models

Shane Horman, Ph.D. Research Investigator III, Head of Advanced Assays Group, Functional Genomics Dept. GNF-Novartis

3-Dimensional multicellular tumor spheroid models have been widely used in oncology research for decades, though in content-limited endeavors. Increasingly dense formats of spheroid plates (96-well to 384-well to 1536-well) have finally enabled high-content screening using these complicated 3D cellular models. Moreover, by combining tumor cells with other cell types from the tumor microenvironment researchers have been able to dissect tumor cell cross-talk important for cancer growth, maintenance and metastasis. Here we present several 1536-well ultra-HTS co-culture spheroid models developed to interrogate anti-tumor immune cell function. For the first time, drugs to modulate immune function are being profiled ex vivo and at ultra-HTS scale, thereby minimizing the excessively-long preclinical drug development timeline.

Using Patient-derived Pancreatic Cancer Organoids Towards Discovering Individually-tailored Clinical Treatments

Ralph J. Garippa, Ph.D. Head of the Gene Editing & Screening (GES) Core Facility Memorial Sloan Kettering Cancer Center

Of all solid cancers, pancreatic has one of the poorest survival rates, thereby presenting a highly unmet medical need. Mutational profiles obtained via whole exome sequencing provide only an incomplete picture of the underlying disease mechanisms. We are utilizing organoid-based 3D cell culture in order to better understand patient functional responses to single/combination drugs and radiation treatments using Corning® Matrigel® matrix 3D microplates.

From Promise to Reality in your Lab: Practical 3D Tools and Applications

Chris Suarez, Ph.D. Field Application Scientist Corning Life Sciences

The workshop will address 3D cell culture techniques, including advanced and novel models. The methods discussed will include the use and analysis of research that includes Corning spheroid microplates, Transwell® permeable supports, and extracellular matrices, including Corning Matrigel matrix. We will discuss some of the unique applications exclusive to these technologies including immune oncology models, blood brain barrier models, and organoid culture.

3D Assay Optimization

Building upon the “Practical 3D Tools and Applications” presentation, we will delve into tips and techniques that will support 3D optimization across various types of 3D cell culture models and assays.

Cell Health Determinations in 3D-Cultures: Challenges and Opportunities

Andrew L. NilesSenior Research Scientist, Assay Designs Group Promega Corporation

This presentation will highlight basic considerations for successfully employing cell health reagents in 3D culture models. Conventional chemistries with validated protocol modifications, and purpose-fit alternative approaches for specific cell health parameters associated with viability, cytotoxicity and apoptosis will be discussed.

Challenges of High Throughput 3D Acquisition and Analysis Using High-content Imaging

Jayne HesleySenior Applications Scientist, Cellular Imaging Molecular Devices, LLC

This presentation will focus on techniques for high throughput 3D acquisition and analysis using high-content imaging. When macroscopic objects are used in an assay, optimization of culture and staining is certainly required but sometimes the bigger challenges are imaging and analyzing extremely large data sets. We will discuss methods for efficiently generating images from samples grown in hydrogels, in round-bottom spheroid microplates, and in non-standard sample formats. We will also share the realistic expectations of the time needed to acquire and analyze such assays as well as storage requirements.

CORNING 3D CELL CULTURE

SURFACESVESSELS MEDIA

The world of 3D cell culture is exploding. More and more scientists are embracing this emerging technology to generate innovative 3D models never before possible. Corning customers are using 3D bioprinting to mimic natural tissues for drug screening, creating organoids to explore the intricacies of diseases in hopes of delivering more effective treatments, producing spheroid cell models, unique methods of high throughput screening, and much more. Corning experts help scientists like you overcome complex challenges to create breakthrough models and deliver what’s next – whatever your 3D approach. Visit www.corning.com/3D to learn how Corning can help you tap the power and potential of 3D cell culture to bring your next big idea to life.

Rock the Science of 3D

© 2

019

Corn

ing

Inco

rpor

ated

. All

righ

ts re

serv

ed.

5/1

9

3D S

UM

MIT

AG

END

A JU

NE-

19

For a listing of trademarks, visit www.corning.com/clstrademarks. All other trademarks are the property of their respective owners.